vivani medical inc - VANI

VANI

Close Chg Chg %
1.28 -0.10 -7.81%

Closed Market

1.18

-0.10 (7.81%)

Volume: 157.26K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Company Overview: vivani medical inc - VANI

VANI Key Data

Open

$1.26

Day Range

1.17 - 1.26

52 Week Range

0.92 - 1.92

Market Cap

$110.38M

Shares Outstanding

86.24M

Public Float

40.21M

Beta

2.30

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.40

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

198.81K

 

VANI Performance

1 Week
 
-10.61%
 
1 Month
 
-0.84%
 
3 Months
 
0.85%
 
1 Year
 
2.61%
 
5 Years
 
-93.89%
 

VANI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About vivani medical inc - VANI

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

VANI At a Glance

Vivani Medical, Inc.
1350 South Loop Road
Alameda, California 94502
Phone 1-415-506-8462 Revenue 0.00
Industry Medical Specialties Net Income -26,609,000.00
Sector Health Technology Employees 42
Fiscal Year-end 12 / 2026
View SEC Filings

VANI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.976
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.934
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.24

VANI Efficiency

Revenue/Employee N/A
Income Per Employee -633,547.619
Receivables Turnover N/A
Total Asset Turnover N/A

VANI Liquidity

Current Ratio 2.711
Quick Ratio 2.711
Cash Ratio 2.459

VANI Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -64.046
Return on Equity -159.622
Return on Total Capital -76.388
Return on Invested Capital -77.843

VANI Capital Structure

Total Debt to Total Equity 121.449
Total Debt to Total Capital 54.843
Total Debt to Total Assets 45.997
Long-Term Debt to Equity 108.462
Long-Term Debt to Total Capital 48.978
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vivani Medical Inc - VANI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
381.00K 357.00K 400.00K 424.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
381.00K 357.00K 400.00K 424.00K
Depreciation
- - - 424.00K
-
Amortization of Intangibles
- - - -
-
COGS Growth
+382.28% -6.30% +12.04% +6.00%
Gross Income
(381.00K) (357.00K) (400.00K) (424.00K)
Gross Income Growth
-382.28% +6.30% -12.04% -6.00%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
20.16M 26.61M 24.28M 27.13M
Research & Development
14.17M 16.97M 15.74M 17.70M
Other SG&A
5.99M 9.64M 8.53M 9.43M
SGA Growth
+124.40% +31.98% -8.76% +11.76%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 700.00K
-
EBIT after Unusual Expense
(21.24M) (26.96M) (24.68M) (27.56M)
Non Operating Income/Expense
7.35M 1.31M 1.19M 947.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(13.89M) (25.65M) (23.49M) (26.61M)
Pretax Income Growth
-55.69% -84.69% +8.44% -13.30%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.89M) (25.65M) (23.49M) (26.61M)
Minority Interest Expense
- - - -
-
Net Income
(13.89M) (25.65M) (23.49M) (26.61M)
Net Income Growth
-55.69% -84.69% +8.44% -13.30%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.89M) (25.65M) (23.49M) (26.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.89M) (25.65M) (23.49M) (26.61M)
EPS (Basic)
-0.3632 -0.5044 -0.4272 -0.4265
EPS (Basic) Growth
+55.46% -38.88% +15.31% +0.16%
Basic Shares Outstanding
38.24M 50.85M 54.98M 62.39M
EPS (Diluted)
-0.3632 -0.5044 -0.4272 -0.4265
EPS (Diluted) Growth
+55.46% -38.88% +15.31% +0.16%
Diluted Shares Outstanding
38.24M 50.85M 54.98M 62.39M
EBITDA
(20.16M) (26.61M) (24.28M) (27.13M)
EBITDA Growth
-127.69% -31.98% +8.76% -11.76%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 4.00
Number of Ratings 2 Current Quarters Estimate -0.085
FY Report Date 06 / 2026 Current Year's Estimate -0.33
Last Quarter’s Earnings -0.08 Median PE on CY Estimate N/A
Year Ago Earnings -0.43 Next Fiscal Year Estimate -0.40
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 1
Mean Estimate -0.09 -0.08 -0.33 -0.40
High Estimates -0.08 -0.07 -0.30 -0.40
Low Estimate -0.09 -0.09 -0.36 -0.40
Coefficient of Variance -8.32 -17.68 -12.86 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Vivani Medical Inc in the News